Braeburn Pharmaceuticals

FDA advisors recommend 2 opioid use disorder drugsTwo opioid use disorder drugs have been recommended for approval by FDA committees.
Two opioid use disorder drug developments to watchNew physician-administered therapies on the horizon may help rein in the opioid epidemic.
Will price impede recently approved implant for opioid addicts?Probuphine implant could be a new option for addicts if obstacles, such as price, don’t get in the way.
Balancing opioid benefits, dangersOpioids are powerful clinical tools that effectively treat pain and have a place in therapy, but it can be difficult to manage the dangers. Here's a look at some of the abuse-deterrent drugs on the horizon.
FDA panel greenlights Probuphine for opioid addictionFDA advisers recommended approval of the first long-acting, subdermal buprenorphine implant (Probuphine, Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals) for the maintenance treatment of opioid addiction.